RECURSION PHARMACEUTICALS INC. - CLASS A COMMON S

Recursion to Participate in Upcoming Investor Conferences

05 Sep 2023 15:30:00 By Nasdaq GlobeNewswire

Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection

05 Sep 2023 06:59:00 By Nasdaq GlobeNewswire

Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds

08 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results

08 Aug 2023 06:58:00 By Nasdaq GlobeNewswire

Recursion to Participate in Upcoming Investor Conference

01 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships

26 Jul 2023 17:58:00 By Nasdaq GlobeNewswire

Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

12 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem

26 Jun 2023 10:48:04 By Nasdaq GlobeNewswire

Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled

13 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Recursion to Participate in Upcoming Investor Conferences

01 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Altitude Lab Relocates to Gateway’s BioHive Hub

25 May 2023 15:00:00 By Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results

08 May 2023 07:14:39 By Nasdaq GlobeNewswire

Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities

08 May 2023 06:59:00 By Nasdaq GlobeNewswire